lenalidomide maintenance in patients with primary central nervous system lymphoma

Phase II trial of lenalidomide maintenance after high–dose methotrexate-based immunochemotherapy in patients with primary central nervous system lymphoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CRIS

Registry ID

KCT0007015

Enrollment

Registered

2022-02-18

Start date

2022-04-01

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Lenalidomide 15 mg D1-21 q 28 days for 1 year Lenalidomide maintenance therapy begins 6 weeks ± 7 days from the date of the last high-dose MTX based immunochemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received immunochemotherapy containing high-dose methrexate and rituximab of 2 to 6 cycles as a induction therapy, and had a partial response (PR) or better, but can not undergo autologous hematopoietic stem cell transplantation or whole brain radiotherapy as a consolidation therapy

Exclusion criteria

Exclusion criteria: Patients who are scheduled to undergo autologous hematopoietic stem cell transplantation or whole brain radiotherapy after high-dose methrexate-based immunochemical therapy.

Design outcomes

Primary

Measure	Time frame
Progression-free survival rate at 2 years	—

Secondary

Measure	Time frame
Overall response rate, overall survival rate, adverse events	—

Countries

Korea, Republic of

Contacts

Public ContactJEONG-OK LEE

Seoul National University Bundang Hospital

jeongok77@gmail.com+82-31-787-7055

Outcome results